Publicacions en col·laboració amb investigadors/es de Hospital Universitario de la Princesa (11)

2023

  1. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

2021

  1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  2. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

    Molecular Oncology, Vol. 15, Núm. 9, pp. 2363-2376

2019

  1. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

    Lung Cancer, Vol. 134, pp. 72-78

  2. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

    Annals of Oncology, Vol. 30, Núm. 2, pp. 290-296

2018

  1. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38

2012

  1. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer

    Cancer Chemotherapy and Pharmacology, Vol. 70, Núm. 6, pp. 883-890

2011

  1. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

    Clinical and Translational Oncology, Vol. 13, Núm. 6, pp. 411-418

2010

  1. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

    Journal of Translational Medicine, Vol. 8

2005

  1. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 16, Núm. 7, pp. 1081-1086

2004

  1. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: Randomized phase II trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study

    Annals of Oncology, Vol. 15, Núm. 1, pp. 79-87